Ciprofol Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Ciprofol Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 24 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Ciprofol can convert its Small molecule drug profile and GABAA receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Ciprofol (query alias: Ciprofol) |
|---|---|
| Modality / target | Small molecule drug; GABAA receptor; GABAA receptor agonists |
| Highest global status | Approved |
| Originator | Haisco Pharmaceutical Group Co., Ltd. |
| Active developers | Shenyang Haisike Pharmaceutical Co., Ltd., Haisco Usa Pharmaceuticals, Inc., Haisco Pharmaceutical Group Co., Ltd. |
The MCP disease footprint includes Anesthesia, Sedation, Arrhythmias, Cardiac. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07697404 | Phase 4 | Recruiting | 180 | ED95 of ciprofol for LMA insertion in children |
| NCT07696208 | Phase 4 | Not yet recruiting | 124 | Time-weighted average of SBP under the threshold of 120 mmHg after general anesthesia induction until end of surgery |
| NCT07718152 | Phase 4 | Not yet recruiting | 60 | Within-participant difference in lower-extremity MEP peak-to-peak amplitude between ciprofol and remimazolam periods |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Ciprofol Versus Propofol for the Prevention of Hypoxia During Gastrointestinal Endoscopy Procedures in Overweight Patients: A Multicenter, Randomized, Controlled Trial
Phase 4; n=1018; evaluation: Positive. Reported fields: Corrective hypoxic measures proportion = 25.7 % ; Corrective hypoxic measures proportion = 20.4 %
A Randomized, Positive and Placebo-Controlled Study to Evaluate the Effects of HSK3486 Administration on Cardiac Repolarization in Healthy Subjects
Phase 1; n=48; evaluation: not stated. Reported fields: -; -; -
Efficacy and safety of ciprofol for sedation/anesthesia in patients undergoing hysteroscopy: a prospective, randomized, non-inferiority trial
Not Applicable; n=124; evaluation: Positive. Reported fields: Success rate of hysteroscopy = 100 % ; Success rate of hysteroscopy = 100 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Ciprofol addresses Anesthesia, Sedation, Arrhythmias, Cardiac. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 107 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: GABAA receptor records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-06-10 | Dong-A ST Licenses Out Epilepsy Drug Cenobamate for Australia, New Zealand | Approved | Financial terms not disclosed |
| 2026-04-21 | Tortugas Neuroscience licensed TRTL-107 and TRTL-913 from China’s Hansoh | Phase 2 | Financial terms not disclosed |
| 2026-04-08 | Assertio signed and closed an agreement to sell all non-Rolvedon assets to Cosette Pharmaceuticals | Approved | US$35.0M upfront |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Pharmaceutical combination containing etomidate derivative and ciprofol and use thereof”. The milestone feed surfaced a patent-application signal described as “Use of ciprofol injection for surgical general anesthesia induction and maintenance in pediatric patient”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 24 July 2026. Counts and status fields may change as source records update.
